Emerging clinical data indicates about 3% of patients with prostate cancer have a high tumor mutation burden (microsatellite instability-high or mismatch repair deficit) and they are responsive to anti-PD-1/PD-L1 agents, with 45% (5 of 11 patients) experiencing durable clinical benefit [21]. The gene discussed is CD274; the disease is Familial prostate cancer.